Document is current
Any future updates will be listed below
-
Authors
Brenner, Thorsten
Skarabis, Annabell
Stevens, Philip
Axnick, Jennifer
Haug, Peter
Grumaz, Silke
Bruckner, Thomas
Luntz, Steffen
Witzke, Oliver
Pletz, Mathias W.
Ruprecht, Thomas M.
Marschall, Ursula
Altin, Sibel
Greiner, Wolfgang
Berger, Marc Moritz https://orcid.org/0000-0001-6771-3193
,
-
Funding
Funding for this research was provided by:
Innovation Fund of the Federal Joint Committee (NVF1_2020-060)
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 28 September 2021
First Online: 18 October 2021
Declarations
:
: The clinical trial protocol and the corresponding documents will be approved by the Ethics Committees of all participating centers. A first positive ethical vote has been given by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (Trial Code No. 20-9352-BO). Written, informed consent to participate will be obtained from all participants or their legal representatives.
: Not applicable.
: TBre received research funding from the Innovation Fund of the Federal Joint Committee (G-BA), Dietmar Hopp Stiftung, German Research Foundation (DFG), Heidelberg Foundation of Surgery, and Stiftung Universitätsmedizin Essen. Furthermore, TBre received honoraria for lectures or advisory board participation from Biotest AG, Baxter Deutschland GmbH, Schöchl medical education GmbH, Boehringer Ingelheim Pharma GmbH, CSL Behring GmbH, Astellas Pharma GmbH, B. Braun Melsungen AG, and MSD Sharp & Dohme GmbH. PS, JA, PH, and SG are minority shareholders and/ or employees of Noscendo.
